Clinical Genomics appoints two new VPs
04 February, 2015 by Dylan Bushell-EmblingClinical Genomics has appointed a new VP for APAC and VP of regulatory affairs as part of a global expansion strategy for its colorectal cancer screening products.
Novogen on track to regaining Nasdaq compliance
03 February, 2015 by Dylan Bushell-EmblingNovogen (ASX:NRT) has completed placements to ensure it regains compliance with Nasdaq listing rules, while CEO Dr Graham Kelly prepares to present at two investor conferences over the next two weeks.
Goodnow joins Garvan as deputy director
02 February, 2015Professor Chris Goodnow has taken up the position of deputy director at the Garvan Institute of Medical Research.
GTG secures new BREVAGen contracts
30 January, 2015 by Dylan Bushell-EmblingShares in Genetic Technologies (ASX:GTG) more than doubled after the company revealed that up to six new breast centres will stock its BREVAGen breast cancer risk test in Q1, with more contracts on the way.
Alchemia to pursue deals for core assets
29 January, 2015 by Dylan Bushell-EmblingAlchemia (ASX:ACL) plans to explore sales or partnership opportunities for its core assets fondaparinux, its HyACT oncology platform and its VAST drug discovery platform.
Sienna's long-serving CEO steps down
28 January, 2015 by Dylan Bushell-EmblingSienna Cancer Diagnostics CEO Dr Kerry Hegarty has resigned from the role after a 10-year term, as part of the company's strategic transformation plan.
Sirtex gets government grant for brain cancer R&D
28 January, 2015 by Dylan Bushell-EmblingSirtex Medical (ASX:SRX) has secured a $50,000 Research Connections grant for a project to adapt its SIR-Spheres technology to treat brain cancer and other diseases.
Australia Day honours for medical researchers
27 January, 2015Professor Brendan Crabb, Professor John Funder and Professor Jeremy Chapman were awarded Companions of the Order of Australia in the Australia Day 2015 Honours List for their contributions to medicine.
Viralytics commences bladder cancer trial
27 January, 2015 by Dylan Bushell-EmblingViralytics (ASX:VLA) has enrolled the first patient for a UK phase I trial of Cavatak in non-muscle invasive bladder cancer.
Prima BioMed in for seven-figure payday
27 January, 2015 by Dylan Bushell-EmblingGSK has commenced a phase I trial of antibody technology licensed from Prima BioMed's newly acquired Immutep subsidiary, triggering a seven-figure milestone payment.
Prima appoints head of investor relations
21 January, 2015 by Dylan Bushell-EmblingPrima BioMed (ASX:PRR) has named Stewart Roberts its head of investor relations, as the company seeks to build on the acquisition of Immutep by attracting new shareholders.
Monash, Janssen-Cilag tackle autoimmune diseases
14 January, 2015 by Dylan Bushell-EmblingMonash University has entered a collaborative research partnership with Janssen-Cilag to explore potential new treatments for autoimmune diseases including rheumatoid arthritis.
Imugene draws up protocol for HER-Vaxx trial
13 January, 2015 by Dylan Bushell-EmblingImugene (ASX:IMU) has drawn up the protocol for a phase Ib/II trial of HER-Vaxx in gastric cancer and appointed a nonclinical CRO to help guide the IND process for the drug.
Sirtex completes recruitment for SIR-Spheres trial
09 January, 2015 by Dylan Bushell-EmblingSirtex Medical (ASX:SRX) has now recruited over 1000 patients for its three concurrent trials of its liver cancer treatment SIR-Spheres microspheres.
Sienna secures first deal for SCD-A7
08 January, 2015 by Dylan Bushell-EmblingSienna Cancer Diagnostics has won the first commercial agreement covering the bladder cancer screening technology based on its SCD-A7 antibody.
